Barclays initiated coverage of Bristol Myers (BMY) with an Overweight rating and $75 price target The company is facing a “patent cliff” with looming loss of exclusivities for Eliquis and Opdivo, but “green shoots” for its pipeline are beginning to emerge, the analyst tells investors in a research note. The firm sees upside estimate potential for multiple expansion for Bristol shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- FDA to begin requiring on clinical trial
- FDA to begin requiring one clinical trial in drug approvals
- Balanced Risk-Reward Keeps Bristol-Myers Squibb Rated Hold as CELMoD Franchise Awaits Key Iberdomide Data
- Bristol Myers says FDA accepts NDA for iberdomide
- Bristol Myers’ treatment of follicular lymphoma granted FDA orphan designation